News & Publications

NEWS & PUBLICATIONS

Learn more about Prous Institute and our progress in drug discovery, technology, industry partnerships, collaborations and scientific articles.


San Francisco, March 15, 2012 - Prous Institute for Biomedical Research and the FDA Center for Drug Evaluation and Research (CDER)  have found promising validation results for the predictive performance of mutagenicity models using Prous Institute's Symmetry® computational software and the FDA/NCTR Mold2 descriptor package. Prous Institute and the FDA/CDER are jointly presenting the...


San Francisco, March 14, 2012 - Prous Institute for Biomedical Research has reported encouraging statistically significant results for cross-validation and external validation of cytochrome P450 3A4 and 2D6 inhibitor models created using its BioEpisteme® predictive software. The findings are a result of an FDA-approved research collaboration and are being presented jointly with the FDA Center ...


Compounds developed using Prous Institute Symmetry® Drug Discovery Platform open new avenues in cancer treatment Prous Institute for Biomedical Research has announced the recent publishing of its new WIPO patent application. The cited compounds figured among the new magnolol and honokiol derivatives obtained at the Prous Institute for Biomedical Research that have shown inhibitory activ...


Barcelona, January 12, 2012 – Prous Institute for Biomedical Research is proud to announce the nomination call for the 2012 Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery. Following their tradition of drug discovery science and technology, Prous Institute has donated the award biennially since 2004, acknowledging outstanding achievements in the field of m...

Category: News, Technology

Washington D.C., USA: The Food and Drug Administration's Center for Food Safety and Applied Nutrition(FDA/CFSAN) and Prous Institute for Biomedical Research (PIBR) will work jointly under a 5 year research collaboration agreement (RCA) to develop hypothesis based in silico predictive tools that are consistent with CFSAN's and FDA’s Critical Path Initiative.This research will benefit CFSAN, t...

Page 9 of 11First   Previous   2  3  4  5  6  7  8  [9]  10  11  Next   Last